References
- References
- Drucker DJ. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad USA 1996;93:7911–6.
- Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol 1997;273:E77–84.
- Chance WT, Foley-Nelson T, Thomas I, Balasubramaniam A. Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. Am J Physiol 1997;273: G559–63.
- Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334:841–8.
- Holst JJ. Enteroglucagon. Annu Rev Physiol 1997;59:257–71.
- Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, et al. Regulation of the biological activity of glucagonlike peptide 2 by dipeptidyl peptidase IV. Nat Biotechnol 1997;15: 673–7.
- Drucker DJ, Yusta B, Boushey RP, DeForest L, Brubaker PL. Human [Gly2 ] GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 1999; 276:G79–91.
- Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109:1344–67.
- Bregenholt S, Delbro D, Claesson MH. T-cell transfer and cytokine/TCR gene deletion models in the study of inflammatory bowel disease. APMIS 1997;105:655–62.
- Claesson MH, Bregenholt S, Bonhagen K, Thoma S, Möller P, Grusby MJ, et al. Colitis-inducing potency of CD4+ cells in immunodeficient, adoptive hosts depends on their state of activation, IL-12 responsiveness, and CD45RB surface phenotype. J Immunol 1999;162: 3702–10.
- Bregenholt S, Brimnes J, Reimann J, Claesson MN. Accumulation of immunoglobulin-containing cells in the gut mucosa and presence of faecal immunoglobulin in severe combined immunodeficient (scid) mice with T cell-induced inflammatory bowel disease (IBD). Clin Exp Immunol 1998;114:19–25.
- Holst JJ, Bersani M. Assay for peptide products of somatostatin gene expression. In: Conn PM, editor. Methods in neurosciences. Vol 5. Neuropeptide technology. San Diego (CA): Academic Press; 1991. p. 3–22.
- Wojdemann M, Wettergren A, Hartmann B, Holst JJ. Glucagonlike peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998;33:828–32.
- Holst JJ. Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33–39) of glicentin. Biochem J 1982;207:381–8.
- Ørskov C, Rabenhøj L, Kofod H, Wettergren A, Holst JJ. Production and secretion of amidated and glycine-extended glucagons-like peptide-1 (GLP-1) in man. Diabetes 1994;43: 535–9.
- Buhl T, Thim L, Kofod H, Ørskov C, Harling H, Holst JJ. Naturally occurring products of proglucagon 111–160 in the porcine and human small intestine. J Biol Chem 1988;263: 8621–4.
- Bregenholt S, Claesson MH. Increased intracellular Th1 cytokines in Scid mice with inflammatory bowel disease. Eur J Immunol 1998;28:379–89.
- Xiao Q, Boushey RP, Drucker DJ, Brubaker PL. Circulating glucagon-like peptide-2 (GLP-2) in normal humans and patients with inflammatory bowel disease [abstract]. Gastroenterology 1999;116:A688.
- Claesson MH, Rudolphi A, Kofoed S, Poulsen SS, Reimann J. CD4+ T lymphocytes injected into severe combined immunodeficient (SCID) mice lead to an inflammatory and lethal bowel disease. Clin Exp Immunol 1996;104: 491–500.